Enveric Biosciences, Inc. (ENVB) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.10
↓-99% vs avg
5yr avg: 8.49
30Y Low0.3·High153.3
ROE
↓
-420.5%
↑-46% vs avg
5yr avg: -287.8%
30Y Low-420%·High83%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.1·High0.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ENVB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Enveric Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $764175 | $1M | $3M | $42M | $65M | $329M | $368M | $179M | $62M | $250M | $218M |
| Enterprise Value | $-3913316 | $-3462461 | $464554 | $40M | $47M | $312M | $366M | $184M | $66M | $252M | $222M |
| P/E Ratio → | -0.04 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | 4.49 | 1.45 | 5.14 | 6.03 |
| P/B Ratio | 0.10 | 0.29 | 1.70 | 21.52 | 4.17 | 14.77 | 107.63 | 16.87 | 5.78 | 12.86 | 18.69 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ENVB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | 4.60 | 1.53 | 5.19 | 6.13 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ENVB Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -420.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 20.4% | 20.9% | 21.1% | 18.1% |
| Operating Margin | — | — | — | — | — | — | — | -15.8% | -16.6% | -24.6% | -14.9% |
| Net Profit Margin | — | — | — | — | — | — | — | -14.0% | -39.3% | -18.7% | -7.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -420.5% | -420.5% | -539.6% | -0.2% | -97.7% | -380.8% | -97.8% | -52.4% | -111.9% | -58.3% | -46.6% |
| ROA | -296.7% | -296.7% | -259.4% | -0.1% | -80.0% | -317.9% | -47.2% | -20.5% | -41.3% | -19.8% | -10.4% |
| ROIC | — | — | — | — | -990.4% | -558.9% | -49.8% | -32.0% | -29.5% | -48.5% | -40.5% |
| ROCE | -304.1% | -304.1% | -542.8% | -187.8% | -99.3% | -185.0% | -80.0% | -49.5% | -38.9% | -49.2% | -33.6% |
ENVB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $5M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.00 | 0.01 | — | 0.46 | 0.48 | 0.37 | 0.43 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.12 | -1.41 | -1.17 | -1.14 | -0.77 | -0.46 | 0.42 | 0.36 | 0.12 | 0.31 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -82777.81 | -82777.81 | — | -4655.56 | -3801.13 | -5469.31 | -14.42 | -6.55 | -13.45 | -18.94 | -7.69 |
Net cash position: cash ($5M) exceeds total debt ($0)
ENVB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Enveric Biosciences, Inc.'s current ratio of 5.38x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.53x to 5.38x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.38 | 5.38 | 1.84 | 1.53 | 4.61 | 8.51 | 3.35 | 0.53 | 0.68 | 0.48 | 0.79 |
| Quick Ratio | 5.38 | 5.38 | 1.84 | 1.53 | 4.61 | 8.51 | 3.35 | 0.53 | 0.68 | 0.48 | 0.79 |
| Cash Ratio | 5.09 | 5.09 | 1.50 | 0.98 | 4.44 | 8.33 | 2.32 | 0.03 | 0.09 | 0.16 | 0.12 |
| Asset Turnover | — | — | — | — | — | — | — | 1.60 | 1.45 | 0.93 | 0.91 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | 58.38 | 66.82 | 66.39 | 81.39 |
ENVB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Enveric Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 100.0% | 100.0% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 40.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 40.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 0.0% |
| Shares Outstanding | — | $334719 | $41908 | $179922 | $173189 | $39362 | $9589 | $2203 | $396 | $250 | $218 |
Peer Comparison
Compare ENVB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ENVBYou | $764175 | -0.0 | — | — | — | — | -420.5% | — | — |
 CMPS | $1B | -4.1 | — | — | — | — | -565.3% | — | — |
 MNMD | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 ATAI | $1B | -1.4 | — | — | 75.3% | -2439.7% | -389.9% | -57.0% | — |
 CYBN | $304M | -13.7 | — | — | — | — | -42.8% | -115.8% | — |
 LSCC | $21B | 6893.3 | 364.7 | 158.9 | 68.2% | 2.9% | 0.4% | 1.8% | 1.4 |
 SILO | $6M | -0.8 | — | — | -1128.9% | -5937.0% | -74.6% | -239.1% | — |
 DRUG | $471M | -48.3 | — | — | — | — | -27.9% | — | — |
 JAZZ | $14B | -38.5 | 23.7 | 10.9 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 INVA | $2B | 6.8 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 AXSM | $13B | -68.1 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ENVB — Frequently Asked Questions
Quick answers to the most common questions about buying ENVB stock.
What is Enveric Biosciences, Inc.'s P/E ratio?
Enveric Biosciences, Inc.'s current P/E ratio is -0.0x. The historical average is 10.4x.
What is Enveric Biosciences, Inc.'s ROE?
Enveric Biosciences, Inc.'s return on equity (ROE) is -420.5%. The historical average is -84.5%.
Is ENVB stock overvalued?
Based on historical data, Enveric Biosciences, Inc. is trading at a P/E of -0.0x. Compare with industry peers and growth rates for a complete picture.